Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases (AVITHRAPID)

Grant Agreement ID
Implementation period
01/01/2024 – 30/06/2028
Fraunhofer Society for the Advancement of Applied Research, Germany
Call for proposal
Total Budget
€ 7 459 253,75 (EU contribution € 7 459 253,75)
Project participants
Latvian Institute of Organic Synthesis (LIOS), Latvia
University of Tuscia, Italy
EuResist Network, Italy
Elettra Sincrotrone Trieste, Italy
University of Naples Federico II, Italy
First Health Pharmaceuticals, Netherlands
National Institute of Infectious Diseases Lazzaro Spallanzani, Italy
University of Siena, Italy
Instituto de Medicina Molecular João Lobo Antunes, Portugal
University of Cagliari, Italy
University of Tours, France
French National Institute of Health and Medical Research (3rd party)
Tor Vergata University of Rome, Italy
VSB – Technical University of Ostrava, Czechia
Dompe’ Farmaceutici – S.P.A., Italy
National Research Institute for Agriculture, Food and Environment, France
Swiss Tropical and Public Health Institute, Switzerland
Chelonia SA, Switzerland
Project leader in LIOS
Prof. Aigars Jirgensons
LIOS Budget
€ 303 750.00 (EU contribution € 303 750.00)

The European Consortium “Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases” (AVITHRAPID) aims to support the search for novel broad-spectrum antiviral compounds by advancing multiple approaches.

Building on a pre-existing set of bioactive small molecules, which are at least at the validated hit level, AVITHRAPID strives for the development of pre-clinical candidates targeting several viruses. This will be achieved by combining the relevant expertise for pre-clinical drug discovery, including molecular modeling, biochemical and cell-based assays, X-ray crystallography, medicinal chemistry, biophysical binding studies, ADMETox profiling, in vitro and in vivo PK, as well as animal disease models. In addition, the consortium aims to conduct a Phase 2a clinical trial for a small molecule developed against Zika virus.  Moreover, the consortium aims to identify and validate further viral targets and thereby contribute to the search for novel antiviral targets.

As a consequence of the activities in AVITHRAPID, an early-stage drug discovery pipeline will be established that can be used to rapidly identify and develop novel antiviral compounds against emerging diseases.